A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events
This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.
Inclusion Criteria:
Exclusion Criteria:
Phoenix, Arizona 85018, United States
Phoenix, Arizona 85018, United States
Colorado Springs, Colorado 80909, United States
Saint Augustine, Florida 32086, United States
Saint Augustine, Florida 32086, United States
Fremont, Nebraska 68025, United States
Plano, Texas 75093, United States
Saint-Georges, Beauce, Quebec G5Y 4T8, Canada
Olomouc, 775 20, Czechia
Hexham, Northumberland NE46 1QJ, United Kingdom
Worcester, Worcestershire WR5 1DD, United Kingdom